<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Brown, Jacques</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-Term Safety and Efficacy of Denosumab in Postmenopausal Osteoporosis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-12</style></pages><abstract><style  face="normal" font="default" size="100%">The efficacy and safety of the antiresorptive agent denosumab on bone mineral density and fracture rates were assessed in an open-label extension, crossover trial of the original 3-year, randomized, placebo-controlled Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study. [FREEDOM; NCT00089791; Cummings SR et al. N Engl J Med 2009].</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>